Equities

Forecasts data is unavailable for this security.

Consensus recommendation

As of Apr 21, 2017, the consensus forecast amongst 27 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.
RecommendationsLatest
Buy5
Outperform9
Hold13
Underperform0
Sell0

Share price forecast

The 21 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 77.00, with a high estimate of 95.00 and a low estimate of 61.00. The median estimate represents a 16.23% increase from the last price of 66.25.
High43.4%95.00
Med16.2%77.00
Low-7.9%61.00

Dividends

In 2016, Gilead Sciences Inc reported a dividend of 1.84 USD, which represents a 42.64% increase over last year. The 13 analysts covering the company expect dividends of 2.14 USD for the upcoming fiscal year, an increase of 16.03%.
Div growth (TTM)42.64%
More ▼

Earnings history & estimates

On Feb 07, 2017, Gilead Sciences, Inc. reported 4th quarter 2016 earnings of 2.70 per share. This result was in line with the consensus of the 23 analysts following the company and under-performed last year's 4th quarter results by 18.67%.
The next earnings announcement is expected on May 02, 2017.
Average growth rate-4.90%
Gilead Sciences, Inc. reported annual 2016 earnings of 11.57 per share on Feb 07, 2017.
Average growth rate+87.20%
More ▼

Revenue history & estimates

Gilead Sciences, Inc. had 4th quarter 2016 revenues of 7.32bn. This bettered the 7.15bn consensus of the 21 analysts covering the company. This was 13.94% below the prior year's 4th quarter results.
Average growth rate-3.64%
Gilead Sciences, Inc. had revenues for the full year 2016 of 30.39bn. This was 6.89% below the prior year's results.
Average growth rate+40.47%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.